Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Lixisenatide

Stage Phase 3Stale

Sponsor Sanofi

Route oral and injection

Class GLP-1 RA

Mechanism GLP-1 receptor agonist

Sources

registry, as of 2016-10-11Stale

https://clinicaltrials.gov/study/NCT00976937

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years. Overall status COMPLETED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 319. Conditions Type 2 Diabetes Mellitus. The purpose of this study is to evaluate benefits and risks of lixisenatide (AVE0010), in comparison to sitagliptin, as an add-on treatment to metformin, in obese (body mass index \[BMI\] greater than or equal to 30 kilogram per square meter \[kg/m\^2\]) type 2 diabetic patients Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24 Lixisenatide 18.4 Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24 Sitagliptin 11.9

ClinicalTrials.gov NCT00976937 protocol and results modules

registry, as of 2017-01-30Stale

https://clinicaltrials.gov/study/NCT02274740

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients. Overall status TERMINATED. Phases PHASE2. Lead sponsor Sanofi. Enrollment 2. Conditions Type II Diabetes Mellitus. Primary Objective: To evaluate the ability of lixisenatide to modulate postprandial hyperlipidemia in particular, the effects on plasma changes in triglycerides. Secondary Objectives: The effect of lixisenatide on the following postprandial lipids: apolipoprotein (APO) B48; fr

ClinicalTrials.gov NCT02274740 protocol and results modules

registry, as of 2017-11-29Stale

https://clinicaltrials.gov/study/NCT02745470

Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain. Overall status COMPLETED. Phases NA. Lead sponsor Seoul National University Hospital. Enrollment 30. Conditions Diabetes Mellitus. The aims this study is to explore the effect of a GLP-1 receptor agonist on the degree of brain activation and connectivity obtained by functional magnetic resonance imaging in lean and obese type 2 diabetes

ClinicalTrials.gov NCT02745470 protocol and results modules

fda, as of 2026-11-07

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc

Lixisenatide is a synthetic analogue of human GLP-1, which acts as a GLP-1 receptor agonist.

DailyMed label description

Studies

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

Registry NCT00976937

Phase Phase 3

Status Completed

Enrollment 319

Lixisenatide

Regimen once daily

Weeks 24

Population Type 2 Diabetes Mellitus

Estimand Efficacy

participants with at least 5 percent body weight loss, 18.4 %, week 24Stale

Sitagliptin

Regimen once daily

Weeks 24

Population Type 2 Diabetes Mellitus

Estimand Efficacy

participants with at least 5 percent body weight loss, 11.9 %, week 24Stale

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

Registry NCT02274740

Phase Phase 2

Status Terminated

Enrollment 2

lixisenatide

Regimen once daily

Weeks 2

Population Type II Diabetes Mellitus

metformin

Regimen once daily

Weeks 2

Population Type II Diabetes Mellitus

Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain

Registry NCT02745470

Phase Not applicable

Status Completed

Enrollment 30

Lixisenatide injection

Comparator placebo

Population Diabetes Mellitus

Normal saline

Population Diabetes Mellitus